↓ Skip to main content

Teriflunomide for multiple sclerosis

Overview of attention for article published in Cochrane database of systematic reviews, December 2012
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (58th percentile)
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
2 tweeters
f1000
1 research highlight platform

Citations

dimensions_citation
22 Dimensions

Readers on

mendeley
100 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Teriflunomide for multiple sclerosis
Published in
Cochrane database of systematic reviews, December 2012
DOI 10.1002/14651858.cd009882.pub2
Pubmed ID
Authors

He D, Xu Z, Dong S, Zhang H, Zhou H, Wang L, Zhang S

Abstract

Disease-modifying therapies (DMTs) for multiple sclerosis aim to specifically reduce inflammation in relapsing multiple sclerosis and promote neuroprotection and neurorepair in progressive multiple sclerosis (MS). Most of the currently available disease-modifying drugs (DMDs) require regular and frequent parenteral administration, which imposes a burden on patients and leads to reduced adherence. Not all MS patients respond adequately to current DMDs and, therefore, alternative MS treatments with less invasive routes of administration and new modes of action are required to expand the current treatment repertoire, increase adherence, and thereby improve efficacy. As one of the oral DMDs, teriflunomide is a potentially promising new oral agent in the treatment of relapsing MS. It inhibits dihydro-orotate dehydrogenase (DHODH) and the synthesis of pyrimidine and has selective immunosuppressive and immunomodulatory properties.

Twitter Demographics

The data shown below were collected from the profiles of 2 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 100 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 2 2%
Brazil 2 2%
Spain 2 2%
Finland 1 1%
Ireland 1 1%
Unknown 92 92%

Demographic breakdown

Readers by professional status Count As %
Student > Master 11 11%
Student > Ph. D. Student 11 11%
Student > Bachelor 9 9%
Other 7 7%
Student > Postgraduate 6 6%
Other 12 12%
Unknown 44 44%
Readers by discipline Count As %
Medicine and Dentistry 24 24%
Agricultural and Biological Sciences 7 7%
Nursing and Health Professions 4 4%
Pharmacology, Toxicology and Pharmaceutical Science 3 3%
Immunology and Microbiology 3 3%
Other 9 9%
Unknown 50 50%

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 February 2017.
All research outputs
#6,263,811
of 12,100,779 outputs
Outputs from Cochrane database of systematic reviews
#4,968
of 7,978 outputs
Outputs of similar age
#52,516
of 129,260 outputs
Outputs of similar age from Cochrane database of systematic reviews
#50
of 77 outputs
Altmetric has tracked 12,100,779 research outputs across all sources so far. This one is in the 47th percentile – i.e., 47% of other outputs scored the same or lower than it.
So far Altmetric has tracked 7,978 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 14.6. This one is in the 26th percentile – i.e., 26% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 129,260 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 58% of its contemporaries.
We're also able to compare this research output to 77 others from the same source and published within six weeks on either side of this one. This one is in the 35th percentile – i.e., 35% of its contemporaries scored the same or lower than it.